Myelodysplastic Syndromes
Showing 1 - 25 of 3,172
MDS Trial in Hangzhou (IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine)
Recruiting
- Myelodysplastic Syndromes
- IV Decitabine
- +2 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,Zhejiang University School of Medi
Oct 23, 2023
MDS, Ferroptosis Trial in Pessac (Biological sampling)
Not yet recruiting
- Myelodysplastic Syndromes
- Ferroptosis
- Biological sampling
-
Pessac, France
- +2 more
Jun 19, 2023
MDS Trial in Houston (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2023
MDS Trial run by the National Cancer Institute (NCI) (decitabine and cedazuridine, BMS-986253)
Not yet recruiting
- Myelodysplastic Syndromes
- decitabine and cedazuridine
- BMS-986253
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Biospecimen Acquisition for Myelodysplastic Syndromes
Recruiting
- Myelodysplastic Syndromes
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
MDS Trial (Decitabine/Cedazuridine, Magrolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- (no location specified)
Apr 18, 2023
Acute Myeloid Leukemia, MDS Trial in Rochester, Houston (CTX-712)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Rochester, Minnesota
- +1 more
Feb 15, 2023
Samples of Bone Marrow Aspiration From Myelodysplastic Syndrome
Recruiting
- Myelodysplastic Syndromes
- Blood test
-
Jerusalem, IsraelShaare Zedek Medical Center
Nov 16, 2023
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou
Recruiting
- Allogeneic Hematopoietic Stem Cell Transplantation
- +2 more
- VEN+AZA+Modified BUCY
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 10, 2023
Relapsed / Refractory MDS Trial (NCR300)
Not yet recruiting
- Relapsed / Refractory Myelodysplastic Syndromes
- (no location specified)
May 7, 2022
Interplay Between Immune and Metabolic Programs in
Recruiting
- Myelodysplastic Syndromes
-
Toulouse, FranceIUCT-Oncopole University Hospital
May 17, 2022
Low Risk MDS Trial (R906289 Monosodium (R289 Na))
Not yet recruiting
- Low Risk Myelodysplastic Syndromes
- R906289 Monosodium (R289 Na)
- (no location specified)
Jul 22, 2022
High Grade MDS Trial in Aurora (Omacetaxine, Azacitidine)
Recruiting
- High Grade Myelodysplastic Syndromes
-
Aurora, ColoradoUniverstiy of Colorado Denver
Nov 17, 2022
Myeloid Leukemia, MDS Trial (IFN-?)
Not yet recruiting
- Myeloid Leukemia
- Myelodysplastic Syndromes
- (no location specified)
Nov 15, 2023
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)
Terminated
- MDS
- Myelodysplastic Syndromes
- APR-548 + Azacitidine
-
Tampa, Florida
- +3 more
Jul 20, 2022
Clonal Cytopenia of Undetermined Significance, MDS Trial in Saint Louis (Atorvastatin, Rosuvastatin)
Not yet recruiting
- Clonal Cytopenia of Undetermined Significance
- Myelodysplastic Syndromes
-
Saint Louis, MissouriWashington University School of Medicine
Jul 28, 2022
MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)
Recruiting
- Myelodysplastic Syndromes
- +5 more
- description of MDS pzatient cohort
-
Brest, FranceChu Brest
Oct 27, 2022
Anemia Trial (Luspatercept)
Not yet recruiting
- Anemia
- Luspatercept
- (no location specified)
May 26, 2023
Acute Myeloid Leukemia, MDS Trial in Rochester (Inpatient serious illness care program)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Inpatient serious illness care program
-
Rochester, New YorkUniversity of Rochester
Jun 21, 2022
Haplo-HSCT for Elderly Acute Leukemia/ Myelodysplastic Syndrome
Not yet recruiting
- Acute Leukemia
- Myelodysplastic Syndromes
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 5, 2023
MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)
Active, not recruiting
- Myelodysplastic Syndromes
- cyclophosphamide, fludarabine, and antithymocyte globulin
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023